Tecan Group (TECN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic positioning and business model

• Operates two synergistic business units: Life Sciences and Partnering, enabling innovation from research to clinical applications through shared hardware and software platforms.

• Maintains a strong global presence and manufacturing footprint across North America, Europe, and Asia, supporting resilience and growth.

• Focuses on high-growth areas: genomics, proteomics, cell/tissue workflows, and medtech CDMO, leveraging automation, modular platforms, and digital solutions.

• Modular hardware/software platforms and digital tools like MAPlinx, LabNavigator, and the new Veya platform drive efficiency, differentiation, and democratize lab automation.

• Synergies between divisions enable rapid time-to-market, flexible resource allocation, and seamless scaling from research to clinical applications.

Industry trends and innovation

• Advances in genomics, proteomics, AI-powered drug discovery, and multi-omics integration are fueling demand for automation and precision in labs.

• Personalized medicine, organoid models, and cell & gene therapies are expanding, with partnerships supporting groundbreaking studies.

• Automation is becoming more accessible, addressing labor shortages and workflow complexity in clinical labs with scalable, user-friendly, and regulatory-compliant solutions.

• New platform Veya, launching soon, aims to transform user experience and productivity in lab automation.

• Digital solutions enhance serviceability, fleet management, and remote diagnostics for clients globally.

Financial performance and market dynamics

• 2024 revenue was CHF 934 million, down 11.5% year-over-year, with China and biopharma markets facing significant headwinds and sequential growth observed in H2-24.

• Life Sciences Business showed recovery in H2-24, with positive contributions from consumables, services, and new product demand; Partnering Business saw resilience in certain medtech end markets.

• Cost-saving measures, strict expense controls, and structural changes implemented in 2024 are expected to support profitability in 2025.

• Mid- to high single-digit organic growth and 30-50 bps annual EBITDA margin improvement reconfirmed for the midterm.

• Strong cash generation and a robust financial foundation enable continued investment in R&D, sales, and M&A despite market challenges.